

## Appendix 5

### Differences in trial design between IRONMAN, HEART-FID and FAIR-HF2

IRONMAN: Effectiveness of *Intravenous iron treatment* vs standard care in patients with heart failure and iron deficiency trial

HEART-FID trial: Ferric Carboxymaltose in Heart Failure With Iron Deficiency<sup>1</sup>

FAIR-HF2: Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality<sup>2</sup>

### Population

#### IRONMAN

New or established symptomatic heart failure with reduced ejection fraction (HFrEF): left ventricular ejection fraction (LVEF)  $\leq 45\%$  within the preceding 24 months

AND current or recent (within 6 months) hospitalisation for heart failure or elevated natriuretic peptide

Definition of iron deficiency: ferritin  $< 100 \mu\text{g/L}$  or, provided ferritin  $\leq 400 \mu\text{g/L}$ , TSAT  $< 20\%$

#### HEART-FID

HFrEF with LVEF  $\leq 40\%$  within 24 months or  $\leq 30\%$  within 36 months

AND a documented hospitalisation for heart failure within 12 months or elevated NTproBNP within 90 days

Definition of iron deficiency: ferritin  $< 100 \mu\text{g/L}$ , or between 100 and 300  $\mu\text{g/L}$  if TSAT  $< 20\%$

Estimated enrolment: 3014 participants

#### FAIR-HF2

HFrEF present for at least 12 months (no other data available)

Definition of iron deficiency: ferritin  $< 100 \mu\text{g/L}$ , or between 100 and 300  $\mu\text{g/L}$  if TSAT  $< 20\%$

Estimated enrolment: 1200 participants

### Trial design

IRONMAN: prospective, randomised open-label, blinded endpoint (PROBE) event-driven

HEART-FID: double-blind, placebo controlled

FAIR-HF2: double-blind, placebo controlled

### **Intravenous iron**

IRONMAN: ferric derismaltose

HEART-FID: ferric carboxymaltose

FAIR-HF2: ferric carboxymaltose

### **Primary endpoint**

IRONMAN: Combined rate of recurrent hospitalisations for heart failure and cardiovascular death

HEART-FID: A hierarchical scale of clinical severity comprising (i) death at 12 months, (ii) number of hospitalisations for heart failure at 12 months, or (iii) change in 6-minute walk test distance from baseline to 6 months.

FAIR-HF2: Combined rate of recurrent hospitalisations for heart failure and cardiovascular death

### **Intravenous (IV) iron re-dosing criteria**

IRONMAN: Initial correction at baseline with infusion of IV ferric derisomaltose (for dosing see Table 2, additional dosing at 4 weeks if necessary). Every four months, IV ferric derisomaltose administered if either ferritin <100 µg/L or, provided ferritin ≤400 µg/L, TSAT <25%.

HEART-FID: Initial IV ferric carboxymaltose 750 mg followed by second 750 mg at 7 days (for patients >50kg). Re-dosing every 6 months in the IV ferric carboxymaltose arm according to haemoglobin (<13.5 g/dL in women and <15.0 g/dL in men) and iron status (ferritin <100 ng/mL or 100–300 ng/mL with TSAT<20%)

FAIR-HF2: Initial IV ferric carboxymaltose 1000 mg, followed by optional 500-1000 mg within the first 4 weeks. Subsequent administration of 500 mg IV ferric carboxymaltose every 4 months, except when haemoglobin >16.0 g/dL or ferritin >800 µg/L

<sup>1</sup> Mentz RJ, Ambrosy AP, Ezekowitz JA, et al. Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. *Circ Heart Fail.* 2021;14(5):e008100.

<sup>2</sup> <https://clinicaltrials.gov/ct2/show/NCT03036462> (accessed 4th June 2022)